Skip to main content
The Markets by Proactive
Go to Proactive Australia

Archive

SourceBio reports strong first half as PCR testing accelerates and Cellular Pathology unit recovers

SourceBio reports strong first half as PCR testing accelerates and Cellular Pathology unit recovers

SourceBio International PLC (AIM:SBI, FRA:6J8) executive chairman Jay LeCoque joined Proactive's Stephen Gunnion with details of the company's financial performance for the six months ended 30 June 2021.

LeCoque telling Proactive that SourceBio has made strong progress, with an increase in PCR testing due to coronavirus (COVID-19) and the continued recovery of its Healthcare Diagnostics business unit as demand for Cellular Pathology services accelerates and the recovery of elective surges gathers pace.